Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours

[1]  David C. Smith,et al.  A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma. , 2017, European journal of cancer.

[2]  E. Van Cutsem,et al.  Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  G. Shapiro,et al.  Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma , 2017, British Journal of Cancer.

[4]  E. Winer,et al.  Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study , 2016, Breast Cancer Research and Treatment.

[5]  F. Saad,et al.  Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  T. Powles,et al.  Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. , 2016, The Lancet. Oncology.

[7]  P. Kantoff,et al.  Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[8]  B. Monk,et al.  Incorporation of pazopanib in maintenance therapy of ovarian cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  David C. Smith,et al.  Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Knowles,et al.  Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity , 2014, Nature Reviews Cancer.

[11]  R. Vessella,et al.  Cabozantinib Inhibits Growth of Androgen-Sensitive and Castration-Resistant Prostate Cancer and Affects Bone Remodeling , 2013, PloS one.

[12]  M. Kreissl,et al.  Cabozantinib in progressive medullary thyroid cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  K. Kozloff,et al.  Cabozantinib Inhibits Prostate Cancer Growth and Prevents Tumor-Induced Bone Lesions , 2013, Clinical Cancer Research.

[14]  David C. Smith,et al.  Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Blay,et al.  Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial , 2012, The Lancet.

[16]  I. Ahmad,et al.  Mechanisms of FGFR-mediated carcinogenesis. , 2012, Biochimica et biophysica acta.

[17]  Yongchang Shi,et al.  Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth , 2011, Molecular Cancer Therapeutics.

[18]  D. Berney,et al.  Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib , 2011, Oncogene.

[19]  J. Fargnoli,et al.  The Antiangiogenic Activity in Xenograft Models of Brivanib, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1 Kinases , 2010, Molecular Cancer Therapeutics.

[20]  Helen X. Chen,et al.  Adverse effects of anticancer agents that target the VEGF pathway , 2009, Nature Reviews Clinical Oncology.

[21]  Patrick Schöffski,et al.  Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  G. Jayson,et al.  Correlation of FGF2 tumor expression with tumor response, PFS, and changes in plasma pharmacodynamic (PD) markers following treatment with brivanib alaninate, an oral dual inhibitor of VEGFR and FGFR tyrosine kinases , 2008 .

[23]  J. Fargnoli,et al.  Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215) , 2008, Journal of medicinal chemistry.

[24]  M. Knowles,et al.  FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer , 2007, The Journal of pathology.

[25]  W. Stadler.  The randomized discontinuation trial: a phase II design to assess growth-inhibitory agents , 2007, Molecular Cancer Therapeutics.

[26]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[27]  G. Rosner,et al.  Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  J. Manola,et al.  Phase II Clinical Trial Design: Methods in Translational Research from the Genitourinary Committee at the Eastern Cooperative Oncology Group , 2006, Clinical Cancer Research.

[29]  G. Rosner,et al.  Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Gary L Rosner,et al.  Randomized discontinuation design: application to cytostatic antineoplastic agents. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  O. S. Nielsen,et al.  Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. , 2002, European journal of cancer.

[32]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[33]  Ron Brookmeyer,et al.  A Confidence Interval for the Median Survival Time , 1982 .